Literature DB >> 10981075

The sympathetic nervous system and baroreflexes in hypertension and hypotension.

J L Izzo1, A A Taylor.   

Abstract

Blood pressure and blood volume are closely regulated by the interrelated actions of the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS). Reflex vasoconstriction caused by parallel SNS and RAAS activation is modulated by two interactive negative feedback systems called baroreflex. The aortic-carotid baroreflex systems respond to momentary changes in systolic blood pressure, adjusting the degree of SNS-dependent peripheral vasoconstriction and cardiac output to allow maintenance of a relatively constant perfusion pressure. Cardiopulmonary baroreflexes respond to momentary changes in cardiac filling, adjusting the degree of peripheral venoconstriction and venous return to maintain cardiac preload and stroke volume. Under normal conditions, each baroreflex system exhibits a degree of tonic negative feedback so that it can alter SNS output immediately, providing counterregulatory increases or decreases in pressure or volume to maintain homeostasis. The SNS is inappropriately active in obesity and hypertension and plays a causal or permissive role in all forms of chronic hypertension. If the negative feedback control exerted by the baroreflexes over the SNS and renin-angiotensin-aldosterone system (RAAS) were perfect, chronic hypertension would not occur. Activity of the baroreflexes, however, is chronically altered by maladaptive changes such as cardiac and vascular fibrosis and hypertrophy. Long-term increases in SNS and RAAS activity also exert ongoing deleterious effects on the heart and vasculature by directly facilitating further cardiac hypertrophy and arterial stiffening. These effects appear to contribute to a vicious cycle of chronic hypertension and target organ damage. Other syndromes of abnormal blood pressure (BP) control, including orthostatic hypotension and baroreflex failure are examples of abnormal baroreflex activity and SNS control.

Entities:  

Mesh:

Year:  1999        PMID: 10981075     DOI: 10.1007/s11906-999-0030-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  74 in total

1.  Increase in sympathetic activity with age. I. Role of impairment of arterial baroreflexes.

Authors:  G Hajduczok; M W Chapleau; S L Johnson; F M Abboud
Journal:  Am J Physiol       Date:  1991-04

2.  Brain "ouabain," ANG II, and sympathoexcitation by chronic central sodium loading in rats.

Authors:  B S Huang; S J Veerasingham; F H Leenen
Journal:  Am J Physiol       Date:  1998-04

3.  Effect of age and high blood pressure on baroreflex sensitivity in man.

Authors:  B Gribbin; T G Pickering; P Sleight; R Peto
Journal:  Circ Res       Date:  1971-10       Impact factor: 17.367

4.  Hypertension in the elderly: a pathophysiologic approach to therapy.

Authors: 
Journal:  J Am Geriatr Soc       Date:  1982-05       Impact factor: 5.562

5.  Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man.

Authors:  J W Rowe; J B Young; K L Minaker; A L Stevens; J Pallotta; L Landsberg
Journal:  Diabetes       Date:  1981-03       Impact factor: 9.461

6.  Role of the sympathetic nervous system in blood pressure maintenance in obesity.

Authors:  J R Sowers; L A Whitfield; R A Catania; N Stern; M L Tuck; L Dornfeld; M Maxwell
Journal:  J Clin Endocrinol Metab       Date:  1982-06       Impact factor: 5.958

7.  Impaired cardiopulmonary baroreflex control of renal nerves in renal hypertension.

Authors:  M D Thames; L N Johnson
Journal:  Circ Res       Date:  1985-11       Impact factor: 17.367

8.  Baroreflex regulation of regional blood flow in congestive heart failure.

Authors:  M A Creager; A T Hirsch; V J Dzau; E G Nabel; S S Cutler; W S Colucci
Journal:  Am J Physiol       Date:  1990-05

9.  Neurogenic hypertension produced by lesions of the nucleus tractus solitarii alone or with sinoaortic denervation in the dog.

Authors:  C M Ferrario; K L Barnes; S Bohonek
Journal:  Hypertension       Date:  1981 Nov-Dec       Impact factor: 10.190

10.  The role of the sympathetic nervous system in 2-kidney DOCA-hypertensive Yucatan miniature swine.

Authors:  E J Zambraski; C D Ciccone; J L Izzo
Journal:  Clin Exp Hypertens A       Date:  1986
View more
  6 in total

1.  An Emerging Role for Understanding Orthostatic Hyp'er'tension in the Cardiorenal Syndrome.

Authors:  Jaya P Buddineni; Laxmi Chauhan; Syed T Ahsan; Adam Whaley-Connell
Journal:  Cardiorenal Med       Date:  2011-04-15       Impact factor: 2.041

2.  Baroreceptor reflex dysfunction in the BACHD mouse model of Huntington's disease.

Authors:  Analyne M Schroeder; Dawn H Loh; Maria C Jordan; Kenneth P Roos; Christopher S Colwell
Journal:  PLoS Curr       Date:  2011-11-04

3.  Neurocardiovascular deficits in the Q175 mouse model of Huntington's disease.

Authors:  Tamara S Cutler; Saemi Park; Dawn H Loh; Maria C Jordan; Tomohiro Yokota; Kenneth P Roos; Cristina A Ghiani; Christopher S Colwell
Journal:  Physiol Rep       Date:  2017-06

4.  Class I histone deacetylase inhibitor MS-275 attenuates vasoconstriction and inflammation in angiotensin II-induced hypertension.

Authors:  Yuhee Ryu; Hae Jin Kee; Simei Sun; Young Mi Seok; Sin Young Choi; Gwi Ran Kim; Seung-Jung Kee; Marc Pflieger; Thomas Kurz; Hyung-Seok Kim; Myung Ho Jeong
Journal:  PLoS One       Date:  2019-03-04       Impact factor: 3.240

5.  Caloric restriction prevents obesity- and intermittent hypoxia-induced cardiac remodeling in leptin-deficient ob/ob mice.

Authors:  Aaron A Jones; Sarah N Framnes-DeBoer; Arianne Shipp; Deanna M Arble
Journal:  Front Physiol       Date:  2022-09-08       Impact factor: 4.755

6.  Sitting-induced hemodynamic changes and association with sitting intolerance in children and adolescents: a cross-sectional study.

Authors:  Chunyan Tao; Zhenhui Han; Yongqiang Yan; Zhitao Pan; Hanwen Zhu; Xueying Li; Hongxia Li; Yuanyuan Wang; Ping Liu; Yuli Wang; Min Jiang; Chaoshu Tang; Hongfang Jin; Junbao Du
Journal:  Sci Rep       Date:  2020-08-18       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.